InflaRx (IFRX) Receivables - Other (2020 - 2025)

InflaRx (IFRX) posted Receivables - Other of $2.9 million for Q4 2025, up 71.39% sequentially from $1.7 million in Q2 2025.

InflaRx (IFRX) Receivables - Other (2020 - 2025) Analysis & Trends

InflaRx has reported Receivables - Other for 4 years, with the latest figure at $2.9 million in Q4 2025.

Quarterly Receivables - Other changed N/A year-over-year to $2.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.9 million (changed N/A YoY) and the FY2025 annual result came in at $2.8 million, changed N/A from the prior year.
Receivables - Other rose to $2.9 million in Q4 2025 per IFRX's latest filing, from $1.7 million in the prior quarter.
Over five years, Receivables - Other peaked at $2.9 million in Q4 2025 and troughed at $546010.6 in Q2 2023.
A 3-year average of $1.9 million and a median of $2.2 million in 2022 frame the typical range for Receivables - Other.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	InflaRx	140.30 Mn	-43.96 Mn	2.74 Bn

Download Data